Evidence map›Paper›PMID 38849989›Full record

ArticlemAbs

Structural analysis of light chain-driven bispecific antibodies targeting CD47 and PD-L1.

Pauline Malinge, Xavier Chauchet, Jérémie Bourguignon, Nicolas Bosson, Sébastien Calloud, Tereza Bautzova, Marie Borlet, Mette Laursen, Vinardas Kelpsas, Nadia Rose and 4 more

Abstract read
In one paragraph

Article in mAbs. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Pauline MalingeLight Chain Bioscience - Novimmune SA, Plan-les-Ouates, Switzerland.
Xavier ChauchetLight Chain Bioscience - Novimmune SA, Plan-les-Ouates, Switzerland.
Jérémie BourguignonLight Chain Bioscience - Novimmune SA, Plan-les-Ouates, Switzerland.
Nicolas BossonLight Chain Bioscience - Novimmune SA, Plan-les-Ouates, Switzerland.
Sébastien CalloudLight Chain Bioscience - Novimmune SA, Plan-les-Ouates, Switzerland.
Tereza BautzovaLight Chain Bioscience - Novimmune SA, Plan-les-Ouates, Switzerland.
Marie BorletLight Chain Bioscience - Novimmune SA, Plan-les-Ouates, Switzerland.
Mette LaursenSARomics Biostructures AB, Lund, Sweden.
Vinardas KelpsasSARomics Biostructures AB, Lund, Sweden.
Nadia RoseSARomics Biostructures AB, Lund, Sweden.
Franck GueneauLight Chain Bioscience - Novimmune SA, Plan-les-Ouates, Switzerland.
Ulla RavnLight Chain Bioscience - Novimmune SA, Plan-les-Ouates, Switzerland.
Giovanni MagistrelliLight Chain Bioscience - Novimmune SA, Plan-les-Ouates, Switzerland.
Nicolas FischerLight Chain Bioscience - Novimmune SA, Plan-les-Ouates, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In contrast to natural antibodies that rely mainly on the heavy chain to establish contacts with their cognate antigen, we have developed a bispecific antibody format in which the light chain (LC) drives antigen binding and specificity. To better understand epitope-paratope interactions in this context, we determined the X-ray crystallographic structures of an antigen binding fragment (Fab) in complex with human CD47 and another Fab in complex with human PD-L1. These Fabs contain a κ-LC and a λ-LC, respectively, which are paired with an identical heavy chain (HC). The structural analysis of these complexes revealed the dominant contribution of the LCs to antigen binding, but also that the common HC provides some contacts in both CD47 and PD-L1 Fab complexes. The anti-CD47 Fab was affinity optimized by diversifying complementary-determining regions of the LC followed by phage display selections. Using homology modeling, the contributions of the amino acid modification to the affinity increase were analyzed. Our results demonstrate that, despite a less prominent role in natural antibodies, the LC can mediate high affinity binding to different antigens and neutralize their biological function. Importantly, Fabs containing a common variable heavy (VH) domain enable the generation of bispecific antibodies retaining a truly native structure, maximizing their therapeutic potential.

Indexed as

Antibodies, BispecificB7-H1 AntigenCD47 AntigenImmunoglobulin Fab FragmentsCrystallography, X-RayHumansImmunoglobulin Light ChainsModels, MolecularAntibodies, BispecificB7-H1 AntigenCD274 protein, humanCD47 AntigenCD47 protein, humanImmunoglobulin Fab FragmentsImmunoglobulin Light ChainsBispecificCD47light chainPD-L1structureX-ray crystallography

Identifiers

PMID38849989
PMCPMC11164222

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.